ACTRN12613000941763招募中未知
In bilateral lung transplantation recipients, is an upper limb rehabilitation program more effective than no program in improving pain, strength and bone healing?
The Alfred0 个研究点目标入组 80 人开始时间: 2013年8月26日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 75 Years（—）
- 性别
- All
入选标准
- •bilateral sequential lung transplantation via clam shell or bilateral anterior thoracotomy incisions
排除标准
- •single lung transplantation, interstate patients other than Victorians, age < 18, patients admitted to inpatient rehabilitation facility
研究者
相似试验
进行中（未招募）
不适用
A dual arm factorial randomized trial in patients with ST segment elevation AMI to compare the results of using either anticoagulation with unfractionated heparin plus routine GP IIb/IIIa inhibition with bivalirubin and bail-out GP IIb/IIIa inhibition, and primary angioplasty with stent implantation with either a slow rate-release paclitaxel-eluting stent (TAXUS) or an otherwise identical uncoated bare metal stent (Express) - HORIZONS AMI TrialThe medical condition for this clinical trial is Acute Myocardial Infarction (AMI). AMI is defined as death or necrosis of myocardial cells. It is a diagnosis at the end of the spectrum of myocardial ischemia or acute coronary syndromes. The patients who suffer from AMI are a restricted subpopulation of patients undergoing primary percutaneous coronary intervention (PCI).EUCTR2005-001514-41-DEThe Cardiovascular Research Foundation3,400
进行中（未招募）
不适用
A dual arm factorial randomized trial in patients with ST segment elevation AMI to compare the results of using either anticoagulation with unfractionated heparin plus routine GP IIb/IIIa inhibition with bivalirubin and bail-out GP IIb/IIIa inhibition, and primary angioplasty with stent implantation with either a slow rate-release paclitaxel-eluting stent (TAXUS) or an otherwise identical uncoated bare metal stent (Express) - HORIZONS AMI TrialThe medical condition for this clinical trial is Acute Myocardial Infarction (AMI). AMI is defined as death or necrosis of myocardial cells. It is a diagnosis at the end of the spectrum of myocardial ischemia or acute coronary syndromes. The patients who suffer from AMI are a restricted subpopulation of patients undergoing primary percutaneous coronary intervention (PCI).EUCTR2005-001514-41-DKThe Cardiovascular Research Foundation3,400
进行中（未招募）
不适用
A dual arm factorial randomized trial in patients with ST segment elevation AMI to compare the results of using anticoagulation with either unfractionated heparin plus routine GP IIb/IIIa inhibition with bivalirudin or bail-out GP IIb/IIIa inhibition, and primary angioplasty with stent implantation with either a slow rate-release paclitaxel-eluting stent (TAXUS™) or an otherwise identical uncoated bare metal stent (EXPRESS2™). - HORIZONS AMI TrialEUCTR2005-001514-41-SEThe Cardiovascular Research Foundation3,400
进行中（未招募）
1 期
A dual arm factorial randomized trial in patients with ST segment elevation AMI to compare the results of using either anticoagulation with unfractionated heparin plus routine GP IIb/IIIa inhibition with bivalirubin and bail-out GP IIb/IIIa inhibition, and primary angioplasty with stent implantation with either a slow rate-release paclitaxel-eluting stent (TAXUS) or an otherwise identical uncoated bare metal stent (Express) - HORIZONS AMI TrialThe medical condition for this clinical trial is Acute Myocardial Infarction (AMI). AMI is defined as death or necrosis of myocardial cells. It is a diagnosis at the end of the spectrum of myocardial ischemia or acute coronary syndromes. The patients who suffer from AMI are a restricted subpopulation of patients undergoing primary percutaneous coronary intervention (PCI).EUCTR2005-001514-41-GBThe Cardiovascular Research Foundation3,400
进行中（未招募）
不适用
A dual arm factorial randomized trial in patients with ST segment elevation AMI to compare the results of using either anticoagulation with unfractionated heparin plus routine GP IIb/IIIa inhibition with bivalirubin and bail-out GP IIb/IIIa inhibition, and primary angioplasty with stent implantation with either a slow rate-release paclitaxel-eluting stent (TAXUS) or an otherwise identical uncoated bare metal stent (Express) - HORIZONS AMI TrialThe medical condition for this clinical trial is Acute Myocardial Infarction (AMI). AMI is defined as death or necrosis of myocardial cells. It is a diagnosis at the end of the spectrum of myocardial ischemia or acute coronary syndromes. The patients who suffer from AMI are a restricted subpopulation of patients undergoing primary percutaneous coronary intervention (PCI).EUCTR2005-001514-41-ATThe Cardiovascular Research Foundation3,400